Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials

Fig. 3

Treatment effects of sacubitril/valsartan compared with control treatment (valsartan in PARAGON-HF and enalapril in PARADIGM-HF) in patients with heart failure and diabetes, by left ventricular ejection fraction. A HbA1c reduction from randomization to 48 weeks (n = 5241). B New use of insulin (n = 4778). C New use of non-insulin antihyperglycemic medications (n = 2232). D Hypoglycemia (n = 6173)

Back to article page